BioCatalystWatch
ADILWorkspace / ADIL / OverviewCompany library
ADIAL PHARMACEUTICALS, INC. logo

ADIAL PHARMACEUTICALS, INC.

ADIAL PHARMACEUTICALS, INC. (ADIL)

Website

Price
Market cap
Next catalystFirst half of 2027, subject to regulatory permissionAT177 · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

AT177

Small molecule

AhR

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

AT177

Small molecule

AhR

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Other pipelines

PNV2

PreINDP1P2P3FilingApproved
PNV-5030

Adenosine receptors

PreINDP1P2P3FilingApproved
ADO-5030

Adenosine receptor

PreINDP1P2P3FilingApproved

Approved / commercial

History / paused

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ADIL PR & News

PR & News

ADIL SEC archive